Document ID: chunk:federal_register_of_legislation:F2024L01395:schedule:1:p1
Version: federal_register_of_legislation:F2024L01395
Segment Type: schedule
Provision Reference: sch 1 (pt 1/20)
Character Range: 2253–5740

Schedule 1—Amendments

National Health (Highly Specialised Drugs Program) Special Arrangement 2021 (PB 27 of 2021)
 1.                    Part 1, Division 1, Section 6, definition for "community access medication"
     substitute:
community access medication means any of the following:
 (a) medication for the treatment of hepatitis B;
 (b) medication for the treatment of HIV or AIDS, other than a pharmaceutical benefit that has the drug:
 (i) azithromycin; or
 (ii) doxorubicin ‑ pegylated liposomal; or
 (iii) rifabutin;
 (c) medication for the treatment of opioid dependence;
 (d) medication for continuing treatment of schizophrenia;
 (e) lanreotide;
 (f) octreotide, if:
 (i) the description of its form includes "Injection (modified release)"; and
 (ii) it is for continuing treatment.
 1.                    Part 1, Division 1, Section 7, Subsection (4)
     substitute:

Medical practitioners—medication for the treatment of hepatitis C, lanreotide and octreotide
 (4) A medical practitioner is an authorised prescriber for the following HSD pharmaceutical benefits:
 (a) a benefit that has a drug that is a medication for the treatment of hepatitis C;
 (b) a benefit that has the drug lanreotide;
 (c) a benefit that has the drug octreotide, if:
 (i) the description of its form includes "Injection (modified release)"; and
 (ii) it is for continuing treatment.
 1.                    Schedule 1, entry for Bosentan in the form Tablet 62.5 mg (as monohydrate)
     omit:
         BOSLEER  C11229 C12425 C13495 C13496 C13497 C13499 C13571 C13582 C13632     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entry for Bosentan in the form Tablet 125 mg (as monohydrate)
     omit:
         BOSLEER  C11229 C13495 C13496 C13497 C13499 C13571 C13582 C13632     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entries for Buprenorphine
     substitute:
Buprenorphine  Injection (modified release) 8 mg in 0.16 mL pre‑filled syringe    Injection   Buvidal Weekly   C16051     4    5
               Injection (modified release) 16 mg in 0.32 mL pre‑filled syringe   Injection   Buvidal Weekly   C16051     4    5
               Injection (modified release) 24 mg in 0.48 mL pre‑filled syringe   Injection   Buvidal Weekly   C16051     4    5
               Injection (modified release) 32 mg in 0.64 mL pre‑filled syringe   Injection   Buvidal Weekly   C16051     4    5
               Injection (modified release) 64 mg in 0.18 mL pre‑filled syringe   Injection   Buvidal Monthly  C16015     1    5
               Injection (modified release) 96 mg in 0.27 mL pre‑filled syringe   Injection   Buvidal Monthly  C16015     1    5
               Injection (modified release) 100 mg in 0.5 mL pre‑filled syringe   Injection   Sublocade        C16050     1    5
               Injection (modified release) 128 mg in 0.36 mL pre‑filled syringe  Injection   Buvidal Monthly  C16015     1    5
               Injection (modified release) 160 mg in 0.45 mL pre‑filled syringe  Injection   Buvidal Monthly  C16015     1    5
               Injection (modified release) 300 mg in 1.5 mL pre‑filled syringe   Injection   Sublocade        C16050     1    5
               Tablet (sublingual) 400 micrograms (as hydrochloride)              Sublingual  Subutex          C16009     28   5
               Tablet (sublingual) 2 mg (as hydrochloride)                        Sublingual  Subutex          C16009     84   5
               Tablet (sublingual) 8 mg (as